| 雌激素受体阴性乳腺癌中人表皮生长因子受体2与孕激素受体表达的关系 |
| 投稿时间：2010-01-10 修订日期：2010-03-12 点此下载全文 |
| 引用本文：王宁,王斌,薛春燕,王雅杰.雌激素受体阴性乳腺癌中人表皮生长因子受体2与孕激素受体表达的关系[J].医学研究杂志,2010,39(5):34-38 |
| DOI：
|
| 摘要点击次数: 1789 |
| 全文下载次数: 1407 |
|
| 基金项目:2006年上海市科学技术委员会科技攻关计划（06DZ19505）、上海市重点学科建设项目资助（B905） |
|
| 中文摘要:目的研究雌激素受体（ER）阴性的乳腺癌患者中人表皮生长因子受体2（Her-2）和孕激素受体（PR）表达的关系以及对预后的影响。方法对1180例乳腺癌患者进行回顾性分析，确立ER状态，将PR与Her-2表达的关系进行比较，综合p53和上皮性钙黏蛋白（E-cadherin）状态以及发病年龄、肿瘤直径、肿瘤部位、组织学分级、淋巴结转移状态、是否化疗之间的差异。对影响ER阴性乳腺癌患者无病生存率（DFS）的相关因素进行分析。结果三阴性乳腺癌96例，Her-2过表达乳腺癌164例，PR+/Her-2+ 10例，PR+/Her-2- 28例。三阴性乳腺癌较Her-2过表达乳腺癌更容易发生淋巴结转移（P=0.034），并且三阴性乳腺癌中淋巴结转移≥10枚患者所占的比例（26.0%）明显大于Her-2过表达乳腺癌(12.2%)。三阴性乳腺癌中组织学分级为3级的患者比例明显高于Her-2过表达乳腺癌 (P＜0.0001)。三阴性乳腺癌和Her-2过表达乳腺癌的局部复发率和远处转移率的差异虽无统计学意义，但三阴性乳腺癌的无病生存期（61.85个月）明显短于Her-2过表达乳腺癌 (78.69个月，P＝0.047)。结论与Her-2过表达乳腺癌比较，三阴性乳腺癌的临床表现为侵袭性更强，患者的无病生存期更短，预后更差。 |
| 中文关键词:雌激素受体 孕激素受体 Her-2基因 乳腺肿瘤 预后 |
| |
| Association of Human Epidermal Growth Factor Receptor 2 and Progesterone Receptor Expression in the Estrogen-receptor Negative Breast Cancer Patients |
|
|
| Abstract:ObjectiveWe studied the clinicopathologic characteristics and disease-free survival (DFS) for estrogen receptor-negative(ER-) breast cancer by comparing the status of human epidermal growth factor receptor-2(Her-2) and progesterone receptor(PR). MethodsER-negative expression was identified from 1180 breast cancer patients diagnosed between 2000 and 2007 in Changhai Hospital (Shanghai). We examined differences between triple-negative and Her-2-overexpressing breast cancers in relation to p53 and E-cadherin status, age, tumor size, histological grading, lymph node metastasis and chemotherapy，as well as identified prognostic factors with regards to DFS. ResultsWe identified cases of 96 (12.5%) triple-negative and 164 (21.3%) Her-2-overexpressing phenotypes,respectively. No significant difference in p53 or E-cadherin expression between the triple-negative and Her-2-overexpressing breast cancer was found （P>0.05）. Women with triple negative breast cancer experienced more lymph node metastases （719%︰585%，P=0.034）, with the higher percentage of more than 10 lymph nodes metastases（26.0%）as compared with Her-2-overexpressing breast cancer (12.2%，P=0.034). A higher percentage of histological grade 3 was identified in triple-negative （677%）than in Her-2-overexpressing breast cancer(42.1%，P＜0.0001). No significant difference in local recurrence rate, distant metastasis rate or incidence of recurrence and metastasis between the two phenotypes was found （P>0.05）. However, significantly poorer 5-year DFS was seen in patients with triple negative phenotype （61.85 months）than with Her-2-overexpressing phenotype （78.69 months，P＝0.047). ConclusionTriple-negative breast cancers were more aggressive, and these women had poorer DFS comparing with Her-2-overexpressing ones. |
| keywords:Estrogen receptor Progesterone receptor Her-2 gene Breast neoplasms Prognosis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
